Date
Location
The workshop is co-organised by the European Medicines Agency's (EMA's) Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) in collaboration with the German Stem Cell Network (GSCN) and aims to strengthen dialogue between CAT and the advanced-therapy-medicinal-product (ATMP) developers in industry, academia and hospitals and to facilitate ATMP development and access to the registration procedure.The workshop will allow for the attendees to learn about the development and authorisation of cell-based ATMPs in the European Union and the role of the CAT; to learn about the support provided by EMA and the CAT to ATMP developers; to understand the criteria that CAT applies for the classification of ATMPs; and to hear about CAT's considerations and recent interactions with experts on cell-based therapies for cardiac repair. It will also allow to interact directly with the Regulators in an open forum discussion.